Sun Pharmaceutical Industries has lost an opportunity to launch the generic version of a schizophrenia drug that had generated revenue of Rs 18,150 crore in the United States market in 2009. It, with some other generic drug majors, lost a patent battle against Japanese drug major Otsuka and its US business partner, Bristol Myers Squibb (BMS).
A favourable decision in this regard would have seen the company launching a low-cost version of Abilify (aripiprazole), during the year. The district court of New Jersey had ruled last week that Abilify had patent protection and exclusive marketing rights till 2015.
The company is yet to decide if it should appeal to a higher court. It was among a handful of generic drug manufacturers, including Israel’s Teva Pharmaceuticals and Swiss drug maker Novartis’ generic arm, Sandoz that had filed a patent suit on the drug in the US court. For BMS, which holds marketing rights for the drug in US and Europe, the decision has been very positive. Abilify is the sixth-biggest selling drug in the US.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: